文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

二线抗逆转录病毒治疗中多替拉韦初始补充剂量:一项非比较性、双盲、随机安慰剂对照试验

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
PubMed 文献 · Clin Infect Dis · 2023-01-01

在南非Khayelitsha开展的一项随机、双盲、安慰剂对照2期试验,纳入130例一线替诺福韦-恩曲他滨-依非韦伦(TEE)治疗失败的成人,1:1随机换用替诺福韦-拉米夫定-多替拉韦(TLD)并加用50 mg多替拉韦补充剂量或安慰剂(12小时后服用,共14天)。第24周HIV-1 RNA<50拷贝/mL的比例在补充多替拉韦组为86%(55/64),安慰剂组为82%(53/65);两臂3或4级不良事件频率相似;结论不支持换用TLD时需初始调整多替拉韦剂量。

要点

  • 一线TEE失败者换用TLD时,加用14天多替拉韦补充剂量未见额外获益。
  • 第24周病毒学抑制率:补充多替拉韦组86% vs 安慰剂组82%,研究未设效力比较。
  • 6例(每组3例)符合耐药检测者中无人出现多替拉韦耐药。

核心结论

  • 作者结论认为, findings 不支持对一线TEE治疗失败后换用TLD的患者进行初始多替拉韦剂量调整。

研究设计与样本

  • 随机、双盲、安慰剂对照2期试验,在南非Khayelitsha开展,130例参与者按1:1随机分配(每组65例)。
  • 纳入标准为一线TEE治疗出现病毒学失败(连续2次HIV-1 RNA≥1000拷贝/mL)的成人。
  • 干预为换用TLD并加用50 mg多替拉韦补充剂量或安慰剂,12小时后服用,共14天。
  • 主要结局为第24周HIV-1 RNA<50拷贝/mL的比例;本研究未设效力比较两臂。

主要发现

  • 基线HIV-1 RNA中位数为4.0 log10拷贝/mL,76%的参与者对替诺福韦和拉米夫定均存在基线耐药。
  • 1例参与者死亡,2例失访。
  • 第24周HIV-1 RNA<50拷贝/mL:补充多替拉韦组55/64(86%[95%CI:75%-93%])vs 安慰剂组53/65(82%[95%CI:70%-90%])。
  • 两臂3或4级不良事件频率相似。
  • 截至第24周,6例符合耐药检测的参与者(每组3例)中无人出现多替拉韦耐药。

临床怎么用

  • 作者结论认为不支持对一线TEE治疗失败后换用TLD的患者进行初始多替拉韦剂量调整。

局限性

  • 本研究未设效力比较两臂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dolutegravir concentrations are reduced by efavirenz induction effect necessitating twice-daily dolutegravir dosing when coadministered. Efavirenz induction persists for several weeks after stopping, which could potentially select for dolutegravir resistance if switching occurred with unsuppressed human immunodeficiency virus type 1 (HIV-1) RNA levels and standard dolutegravir dosing. We evaluated the need for a lead-in supplementary dolutegravir dose in adults failing first-line tenofovir-emtricitabine-efavirenz (TEE). METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 2 trial in Khayelitsha, South Africa. Eligible patients had virologic failure (2 consecutive HIV-1 RNA ≥1000 copies/mL) on first-line TEE. Participants were randomly assigned (1:1) to switch to tenofovir-lamivudine-dolutegravir (TLD) with a supplementary 50 mg dolutegravir dose or placebo taken 12 hours later for 14 days. Primary outcome was proportion with HIV-1 RNA <50 copies/mL at week 24. This study was not powered to compare arms. RESULTS: One hundred thirty participants were randomized (65 to each arm). Median baseline HIV-1 RNA was 4.0 log10 copies/mL and 76% had baseline resistance to both tenofovir and lamivudine. One participant died and 2 were lost to follow-up. At week 24, 55 of 64 (86% [95% confidence interval {CI}: 75%-93%]) in the supplementary dolutegravir arm and 53 of 65 (82% [95% CI: 70%-90%]) in the placebo arm had HIV-1 RNA <50 copies/mL. Grade 3 or 4 adverse events were similar in frequency between arms. None of 6 participants (3 in each arm) eligible for resistance testing by 24 weeks developed dolutegravir resistance. CONCLUSIONS: Our findings do not support the need for initial dolutegravir dose adjustment in patients switching to TLD who failed first-line TEE. CLINICAL TRIALS REGISTRATION: NCT03991013.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Zhao Y, Griesel R, Omar Z, et al. Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial. Clin Infect Dis. 2023. PMID: 36645792. doi:10.1093/cid/ciad023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。